Biofrontera Closes Ameluz and RhodoLED Acquisition, Reduces Earnout to 12%-15% of US Net Sales

Biofrontera Inc. has acquired full US rights to Ameluz and RhodoLED from its former parent Biofrontera AG. The company will pay a monthly earnout of 12% in years where annual US net sales are up to $65 million and 15% above that threshold. This replaces the prior transfer-pricing model and is expected to accelerate the company's timeframe to reach break-even. The transaction was funded through an $11 million investment led by existing investors Rosalind Advisors and AIGH Capital Management.